Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season

International Archives of Allergy and Immunology

Volumn 136, Issue 2, 2005, Pages 148-154

  Okubo, Kimihiro ^a   Gotoh, Minoru ^a   Shimada, Kenichi ^a   Ritsu, Masayo ^a   Okuda, Minoru ^b   Crawford, Bruce ^c  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Japan Allergy and Asthma Clinic   (Japan)

^c MAPI VALUES   (United States)

Author keywords

Fexofenadine; Japanese cedar pollinosis; Quality of life; Seasonal allergic rhinitis; Work productivity

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE; PLACEBO; ALLERGEN; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; ETHNIC GROUP; EYE DISEASE; FEMALE; HAY FEVER; HUMAN; JAPAN; JAPANESE CEDAR; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; PATIENT; PHYSICAL ACTIVITY; POLLEN ALLERGY; POPULATION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEASON; STATISTICAL SIGNIFICANCE; SYMPTOM; VALIDATION PROCESS; IMMUNOLOGY; POLLEN; TREATMENT OUTCOME;

ADULT; ALLERGENS; CRYPTOMERIA; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; JAPAN; MALE; POLLEN; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME;

EID: 15844380989     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083322     Document Type: Article

References (27)

1. Committee of Allergic Rhinitis Practice Guideline Preparation. Allergic Rhinitis Practice Guideline, ed 4. Tokyo, Life Science, 2002, chap 2, p 8.
2. Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288-296.
3. Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S, Ware JE, Valentin B, Burtin B: Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-316.
4. Blaiss MS: The role of outcome studies in allergy and clinical immunology. Allergy Asthma Proc 1996;17:355-358.
5. Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
6. Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-365.
7. Reilly MC, Tanner A, Meltzer EO: Work, classroom and activity impairment instruments. Clin Drug Invest 1996;11:278-288.
8. Okuda M, Crawford B, Juniper E, Leahy M: Preparation of Japanese versions of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Work Productivity and Activity Impairment-Allergy Specific Questionnaire (WPAI-AS) (in Japanese). Arerugi 2003;52(suppl 1):70-86.
9. Crawford B, Okuda M, Leahy M: Psychometric validation of a Japanese translation of the RQLQ and WPAI-AS (abstract). J Allergy Clin Immunol 2003;111:428.
10. Bousquet J, van Cauwenberge P, Khaltaev N, ARIA Workshop Group. World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147-S334.
11. Bronsky EA, Falliers CJ, Kaiser HB, Ahlbrandt R, Mason JM: Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998;19:135-141.
12. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J: Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-448.
13. van Cauwenberge P, Juniper E, and the STAR Study Investigating Group: Comparison of the efficacy, safety, and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg, and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-899.
14. Nsouli SM: Treatment of allergic rhinitis: Fexofenadine versus loratadine (abstract P40). Ann Allergy Asthma Immunol 1998;80:109.
15. Kittner B, Austin M, McKenzie D: Pooled analysis of the effects of once daily fexofenadine on nasal congestion and other SAR symptoms (abstract 228). Allergy 2001;56(suppl 68):78.
16. Baba K, Kittner B: Fexofenadine is effective and well tolerated in seasonal allergic rhinitis: Results from a placebo-controlled study in Japan (abstract 523). J Allergy Clin Immunol 2001;107:S159.
17. Paul E, Berth-Jones J, Ortonne J-P, Stern M: Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: A placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998;9:143-149.
18. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J: A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-1078.
19. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-420.
20. Paolieri F, Battifora M, Riccio AM, Bertolini C, Cutolo M, Bloom M, Ciprandi G, Canonica GW, Bagnasco M: Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-607.
21. Marone G, Gentile M, Petraroli A, De Rosa N, Triggiani M: Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 2001;124:249-252.
22. Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J: Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Managed Care 1999;5:S235-S247.
23. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ: Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98:843-845.
24. Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN: Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999;41:948-953.
25. Ministry of Health, Labor and Welfare of Japan: Monthly Labor Survey. April 1, 2002.
26. Thompson AK, Finn AF, Schoenwetter WF: Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43:24-30; erratum in: 2001;45: 960.
27. Meltzer EO, Casale TB, Nathan RA, Thompson AK: Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:311-317.